Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.

10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...

Read more →

Our progress in the funding of medicines for rare disorders

3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...

Read more →

Speeding up access to new medicines in Scotland: abbreviated process

8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...

Read more →

NICE’s new methods reflect society’s values

4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...

Read more →

Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service

5 January 2023 - The main objective of this study was to explore the extent to which the incremental cost effectiveness ...

Read more →

EQ-5D-Y-3L value sets, valuation methods and conceptual questions

12 December 2022 - The measurement and valuation of child health-related quality of life is a rapidly evolving field. ...

Read more →

Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?

2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...

Read more →

Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body

20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years.  ...

Read more →

Has there actually been early resolution for early resolution resubmissions?

15 September 2022 - Following on from this week's article on early re-entry resubmissions, today we took a close look ...

Read more →

Large scale population based surveys linked to administrative health databases as a source of data on health utilities in Australia

8 September 2022 - It is ideal that modelling studies apply health utility values that are compatible, derived using common methods, ...

Read more →

Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.

8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...

Read more →

Esketamine: NICE’s appraisal was unfair, appeal panel rules

8 September 2022 - The decision by the UK National Institute for Health and Care Excellence not to recommend esketamine ...

Read more →

Doctors call for vaccine u-turn from PHARMAC after surge in preventable pneumococcal cases

8 September 2022 - When drug-buying agency PHARMAC switched to a cheaper vaccine covering fewer strains of potentially deadly pneumococcal ...

Read more →

The FDA needs to be more flexible in assessing treatments for rare diseases, like the one that seemed to help my son

7 September 2022 - Every time I read about clinical trials testing possible treatments for rare diseases, I think of ...

Read more →

ICR criticises NICE rejection of olaparib for advanced prostate cancer

6 September 2022 - The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not ...

Read more →